#United States #South San Francisco #Rigel Pharmaceuticals #TAVALISSE #GAVRETO

Rigel Pharmaceuticals Provides Insights on 2025 Revenue and 2026 Prospects

Rigel Pharmaceuticals, Inc. recently shared a significant business update outlining encouraging figures from the fourth quarter of 2025 and a hopeful outlook for 2026. The company reported a preliminary total revenue of approximately $69.8 million for the fourth quarter, which reflects a promising increase compared to the $57.6 million recorded during the same period in 2024. A notable contributor to this growth was net product sales, which reached about $65.4 million, marking a rise from $46.5 million in the previous year.

President and CEO Raul Rodriguez expressed pride in 2025's achievements, highlighting the company's strong commercial execution and financial growth, which included generating $77 million in cash. Looking ahead, Rigel anticipates an optimistic total revenue range for 2026 between $275 to $290 million, projected to stem from net product sales in the vicinity of $255 to $265 million.

Detailed Overview of 2025 Financial Results

Rigel's commercial portfolio indicated promising full-year net product sales of around $232.0 million, representing a substantial 60% growth from the prior year. This performance is attributed to several successful product lines:

• - TAVALISSE® (fostamatinib disodium hexahydrate): Net sales reached approximately $45.6 million, up from $31.0 million in 2024.
• - GAVRETO® (pralsetinib): Recognized net product sales of $10.2 million, increasing from $8.1 million year-over-year.
• - REZLIDHIA® (olutasidenib): Sales contributed $9.6 million, compared to $7.4 million in 2024.

For the entire year 2025, Rigel expects to report a total revenue of about $294.3 million, including significant contract revenues of around $62.3 million. Notably, Rigel saw a considerable uptick in cash, cash equivalents, and short-term investments, projected to total about $154.6 million by the end of 2025, a significant increase over 2024's $77.3 million.

Ongoing Clinical Development Initiatives

Alongside financial advancements, Rigel continues to progress its clinical development pipeline, particularly focusing on R289, an investigational drug in Phase 1b studies aimed at treating lower-risk myelodysplastic syndrome (MDS). Initial data from the trial suggest that R289 is well-tolerated among patients. As part of its study expansion phase, Rigel is actively recruiting participants and plans to finalize a recommended Phase 2 dose in the latter half of 2026.

In recent presentations, Rigel shared promising findings from the American Society of Hematology (ASH) Annual Meeting, demonstrating R289's capability in achieving red blood cell transfusion independence in a noteworthy percentage of evaluated patients. The company also unveiled data supporting the efficacy of its other products, reinforcing Rigel's position as a leader in the development of innovative therapies for hematologic disorders and cancer.

Rigel is scheduled to present its strategic overview at the upcoming 44th Annual J.P. Morgan Healthcare Conference, highlighting its commitment to continuing strong performances through 2026 amidst a landscape of active clinical trials and product development.

Conclusion and Future Plans

As Rigel Pharmaceuticals looks toward 2026, the firm remains committed to driving sustained commercial performance alongside ongoing efforts in clinical development. With a robust pipeline and intent to expand its portfolio, Rigel is well-positioned for success in the coming year, reinforcing its mission to deliver cutting-edge treatments to patients in need.

This overview illustrates Rigel's promising trajectory, characterized by significant commercial growth in 2025 and a strong financial outlook for 2026, enhanced by the advancements in clinical trials and committed leadership.